Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYPB - Cypress BioScience -- Ignore unavailable to you. Want to Upgrade?

To: Jay Lowe who wrote (176)	5/13/1998 4:20:00 PM
From: muddphudd	Read Replies (2) \| Respond to of 586

I am game. Let me know what your plan is. Do you think that CYPB needs to figure out the mechanism of action by the column for FDA approval??

To: Jay Lowe who wrote (176)	5/13/1998 4:25:00 PM
From: Jay Lowe	Respond to of 586

An offline question and answer ... >Do you think that understand the mechanism of the column will be necessary to get >FDA approval? > >Who do you think CYPB will partner up with? Do they have to? They already >have a sales force, no? I don't think that detailed understanding of the mechanism is required for FDA approval ... simply on the basis that they are approved for ITP now and the RA is just an add-on, as I understand it. CYPB had a marketing agreement with Baxter on the column but Baxter wasn't selling it ... I'm guessing it just wasn't a fit for Baxter's sales force. Last CYPB earnings report (on thread) says that they are gearing up their internal sales force for the RA application.